Valuation: Daxor Corporation

Market Cap 61.07M 52.89M 49.3M 45.35M 85.61M 5.81B 86.57M 579M 227M 2.91B 229M 224M 9.62B P/E 2026 *
-49.9x
P/E 2027 * -349x
Enterprise Value 61.07M 52.89M 49.3M 45.35M 85.61M 5.81B 86.57M 579M 227M 2.91B 229M 224M 9.62B EV / Sales 2026 *
5.13x
EV / Sales 2027 * 2.94x
Free-Float
46.74%
Yield 2026 *
-
Yield 2027 * -
1 week-0.47%
Current month-0.19%
1 month+0.96%
3 months-3.44%
6 months-14.52%
Current year-28.95%
1 week 10.11
Extreme 10.1101
11
1 month 10.05
Extreme 10.05
11.97
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 31/12/2012
Director of Finance/CFO 69 27/09/2018
Chief Tech/Sci/R&D Officer - 04/06/2024
Director TitleAgeSince
Director/Board Member 91 31/12/1988
Chairman 56 13/02/2017
Director/Board Member 61 13/02/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%-0.47%+5.12%+9.36% 61.07M
+4.08%+5.10%+24.01%+112.92% 15.24B
+4.55%+9.06%+57.43%+150.99% 12.78B
-0.03%+6.13%-2.52%+33.02% 9.36B
+4.17%+6.44%+36.68%+132.77% 7.86B
-0.80%+0.63%-17.12%-17.29% 7.39B
-0.23%+1.17%+14.94%+42.70% 6.38B
-0.13%-0.49%+9.29%+23.95% 4.76B
-0.65%-2.64%+9.42%+6.37% 4.03B
-0.65%+6.16% - - 3.81B
Average +1.15%+3.34%+15.25%+54.98% 7.96B
Weighted average by Cap. +1.95%+4.38%+20.86%+77.91%

Financials

2026 *2027 *
Net sales 11.9M 10.31M 9.61M 8.84M 16.68M 1.13B 16.87M 113M 44.31M 566M 44.69M 43.71M 1.88B 20.8M 18.01M 16.79M 15.45M 29.16M 1.98B 29.48M 197M 77.45M 990M 78.12M 76.4M 3.28B
Net income -1.2M -1.04M -969K -891K -1.68M -114M -1.7M -11.38M -4.47M -57.09M -4.51M -4.41M -189M -200K -173K -161K -149K -280K -19.02M -284K -1.9M -745K -9.52M -751K -735K -31.51M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
-
Date Price Change Volume
05/08/26 US$10.48 -0.38% 315
04/08/26 US$10.52 -3.04% 3,119
03/08/26 US$10.85 +3.33% 689
31/07/26 US$10.50 - 870
30/07/26 US$0.000000 -100.00% 115
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.48USD
Average target price
22.50USD
Spread / Average Target
+114.69%

Quarterly revenue - Rate of surprise